MEDSIR Presents Final TUXEDO-3 Study Results
The study evaluates patritumab deruxtecan for active brain metastases and leptomeningeal disease. The supplied body is truncated.
The study evaluates patritumab deruxtecan for active brain metastases and leptomeningeal disease. The supplied body is truncated.